GLP‐1 analogues are widely used as treatment for type 2 diabetes mellitus and obesity, and more recently, a dual‐agonist of GLP‐1 and GIP showed promising effects within this field (Coskun et al., 2018). The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.